These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 27355566)
1. Malondialdehyde epitopes as mediators of sterile inflammation. Busch CJ; Binder CJ Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Apr; 1862(4):398-406. PubMed ID: 27355566 [TBL] [Abstract][Full Text] [Related]
2. Malondialdehyde Epitopes as Targets of Immunity and the Implications for Atherosclerosis. Papac-Milicevic N; Busch CJ; Binder CJ Adv Immunol; 2016; 131():1-59. PubMed ID: 27235680 [TBL] [Abstract][Full Text] [Related]
11. Innate sensing of oxidation-specific epitopes in health and disease. Binder CJ; Papac-Milicevic N; Witztum JL Nat Rev Immunol; 2016 Aug; 16(8):485-97. PubMed ID: 27346802 [TBL] [Abstract][Full Text] [Related]
12. Proinflammatory effects of malondialdehyde in lymphocytes. Raghavan S; Subramaniyam G; Shanmugam N J Leukoc Biol; 2012 Nov; 92(5):1055-67. PubMed ID: 22956781 [TBL] [Abstract][Full Text] [Related]
13. Acquired immunogenicity of DNA after modification with malondialdehyde in patients with alopecia areata. Alzolibani AA; Rasheed Z; Al Robaee AA Scand J Clin Lab Invest; 2014 Jun; 74(4):312-21. PubMed ID: 24635877 [TBL] [Abstract][Full Text] [Related]
14. New insights into the resolution of inflammation. Gilroy D; De Maeyer R Semin Immunol; 2015 May; 27(3):161-8. PubMed ID: 26037968 [TBL] [Abstract][Full Text] [Related]
15. Natural regulatory IgM-mediated autoimmune responses directed against malondialdehyde regulate oxidative and nitrosative pathways and coupled with IgM responses to nitroso adducts attenuate depressive and physiosomatic symptoms at the end of term pregnancy. Roomruangwong C; Barbosa DS; de Farias CC; Matsumoto AK; Baltus THL; Morelli NR; Kanchanatawan B; Duleu S; Geffard M; Maes M Psychiatry Clin Neurosci; 2018 Feb; 72(2):116-130. PubMed ID: 29194848 [TBL] [Abstract][Full Text] [Related]
16. Cyclopentenone-containing oxidized phospholipids and their isoprostanes as pro-resolving mediators of inflammation. Friedli O; Freigang S Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Apr; 1862(4):382-392. PubMed ID: 27422370 [TBL] [Abstract][Full Text] [Related]
17. The OSE complotype and its clinical potential. Alic L; Binder CJ; Papac-Milicevic N Front Immunol; 2022; 13():1010893. PubMed ID: 36248824 [TBL] [Abstract][Full Text] [Related]
18. Anti-inflammatory properties of lipid oxidation products. Bochkov VN; Leitinger N J Mol Med (Berl); 2003 Oct; 81(10):613-26. PubMed ID: 13679995 [TBL] [Abstract][Full Text] [Related]
19. Immunization with malondialdehyde-modified low-density lipoprotein (LDL) reduces atherosclerosis in LDL receptor-deficient mice challenged with Porphyromonas gingivalis. Turunen SP; Kummu O; Wang C; Harila K; Mattila R; Sahlman M; Pussinen PJ; Hörkkö S Innate Immun; 2015 May; 21(4):370-85. PubMed ID: 25134521 [TBL] [Abstract][Full Text] [Related]
20. The role of innate immunity in atherogenesis. Hartvigsen K; Chou MY; Hansen LF; Shaw PX; Tsimikas S; Binder CJ; Witztum JL J Lipid Res; 2009 Apr; 50 Suppl(Suppl):S388-93. PubMed ID: 19106070 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]